Immunological modifications during treatment with thymosin α1 plus antiviral therapy in chronic hepatitis C

Annals of the New York Academy of Sciences

Volumn 1194, Issue , 2010, Pages 147-152

  Grandini, E ^a   Cannoletta, F ^a   Scuteri, A ^a   Fortini, C ^a   Loggi, E ^a   Cursaro, C ^a   Riili, A ^a   Di Donato, R ^a   Gramenzi, A ^a   Bernardi, M ^a   Andreone, P ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chronic hepatitis C; Immune response; Lymphocytes; Thymosin alpha 1

Indexed keywords

PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RIBAVIRIN; THYMOSIN ALPHA1;

ADULT; AGED; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; NATURAL KILLER CELL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE;

HEPATITIS C VIRUS;

EID: 77951803196     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05461.x     Document Type: Conference Paper

References (24)

1. Alberti, A., L. Chemello & L. Benvegnù. 1999. Natural history of hepatitis C. J. Hepatol. 31(Suppl. 1): 17-24.
2. Ishii, S. & M.J. Koziel. 2008. Immune responses during acute and chronic infection with hepatitis C virus. Clin. Immunol. 128: 133-147.
3. Rehermann, B. 2009.Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Invest. 119: 1745-1754.
4. Kronenberger, B. & S. Zeuzem. 2009. Current and future treatment options for HCV. Ann. Hepatol. 8: 103-112.
5. Hoofnagle, J.H. & L.B. Seeff. 2006. Peginterferon and ribavirin for chronic hepatitis C. N. Engl. J. Med. 355: 2444-2451.
6. Hügle, T. & A. Cerny. 2003. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev. Med. Virol. 13: 361-371.
7. Camerini, R., A. Ciancio, A. DE Rosa, et al. 2007. Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C. Ann. N.Y. Acad. Sci. 1112: 368-374.
8. Rasi, G., M.G. Mutchnick, D. Di Virgilio, et al. 1996. Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B. J. Viral Hepat. 3: 191-196. (Pubitemid 126733934)
9. Sherman, K.E., M. Sjogren, R.L. Creager, et al. 1998. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology. 27: 1128-1135.
10. Andreone, P., A. Gramenzi, C. Cursaro, et al. 2003. Interferon-alpha combinedwith ketoprofen as treatment of näive patients with chronic hepatitis C: a randomized controlled trial. J. Viral Hepat. 10: 306-309.
11. Poo, J.L., F. Sánchez-Avila, D. Kershenobich, et al. 2004. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24- week interim results of a pilot study. J. Gastroenterol. Hepatol. 6: S79-S81.
12. Andreone, P., C. Cursaro, A. Gramenzi, et al. 2001. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J. Viral Hepat. 8: 194-201.
13. Sjogren,M.H. 2004.Thymalfasin: animmune systemenhancer for the treatment of liver disease. J. Gastroenterol. Hepatol. 19: S69-S72.
14. Garaci, E., C. Favalli, F. Pica, et al. 2007. Thymosin alpha 1: from bench to bedside. Ann. N.Y. Acad. Sci. 1112: 225-234.
15. Ghany, M.G., D.B. Strader, D.L. Thomas, et al. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
16. Bihl, F.K., E. Loggi, J.V. Chisholm III, et al. 2005. Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti-CD3 mAb T-cell expansion and "RecycleSpot". J. Transl. Med. 3: 20.
17. Brenchley, J.M., N.J. Karandikar, M.R. Betts, et al. 2003. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+T cells. Blood 101: 2711-2720.
18. Karandikar, N.J., M.P. Crawford, X. Yan, et al. 2002. Glatiramer acetate (copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J. Clin. Invest. 109: 641-649.
19. Cramp, M.E., S. Rossol, S. Chokshi, et al. 2000. Hepatitis C virus-specific T cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.Gastroenterology 118: 346-355.
20. Kamal, S.M., J. Fehr, B. Roesler, et al. 2002. Peginterferon alone or with ribavirin enhances HCV-specific CD4 Thelper 1 responses in patients with chronic hepatitis C. Gastroenterology 123: 1070-1083.
21. Pilli,M., A. Zerbini, A. Penna, et al. 2007. HCV-Specific T cell response in relation to viral kinetics and treatment putocme (DITTO-HCV-Project). Gastroenterology 133: 1132-1143.
22. Li, Y., T. Zhang, C. Ho, et al. 2004. Natural killer cells inhibit hepatitis C virus expression. J. Leukoc. Biol. 76: 1171-1179.
23. Neau-Cransac, M., J. Foucher, V. De Ledinghen, et al. 2005.Modifications of T-Lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection. Viral Immunol. 18: 197-204.
24. Márquez, M., C. Fernández-Gutiérrez, M. Montes-de- Oca, et al. 2009. Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis. Clin. Exp. Immunol. 158: 219-229.